Cargando…

Differential Expression of Human Peripheral Mononuclear Cells Phenotype Markers in Type 2 Diabetic Patients and Type 2 Diabetic Patients on Metformin

Background: Although peripheral blood mononuclear cells (PBMC) have been demonstrated to be in a pro-inflammatory state in obesity and type 2 Diabetes Mellitus (T2DM), characterization of circulating PBMC phenotypes in the obese and T2DM and the effect of Metformin on these phenotypes in humans is s...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Dubayee, Mohammed S., Alayed, Hind, Almansour, Rana, Alqaoud, Nora, Alnamlah, Rahaf, Obeid, Dana, Alshahrani, Awad, Zahra, Mahmoud M., Nasr, Amre, Al-Bawab, Ahmad, Aljada, Ahmad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189318/
https://www.ncbi.nlm.nih.gov/pubmed/30356719
http://dx.doi.org/10.3389/fendo.2018.00537
_version_ 1783363342907211776
author Al Dubayee, Mohammed S.
Alayed, Hind
Almansour, Rana
Alqaoud, Nora
Alnamlah, Rahaf
Obeid, Dana
Alshahrani, Awad
Zahra, Mahmoud M.
Nasr, Amre
Al-Bawab, Ahmad
Aljada, Ahmad
author_facet Al Dubayee, Mohammed S.
Alayed, Hind
Almansour, Rana
Alqaoud, Nora
Alnamlah, Rahaf
Obeid, Dana
Alshahrani, Awad
Zahra, Mahmoud M.
Nasr, Amre
Al-Bawab, Ahmad
Aljada, Ahmad
author_sort Al Dubayee, Mohammed S.
collection PubMed
description Background: Although peripheral blood mononuclear cells (PBMC) have been demonstrated to be in a pro-inflammatory state in obesity and type 2 Diabetes Mellitus (T2DM), characterization of circulating PBMC phenotypes in the obese and T2DM and the effect of Metformin on these phenotypes in humans is still ill-defined and remains to be determined. Methods: Thirty normal healthy adult volunteers of normal weight, 30 obese subjects, 20 obese newly diagnosed diabetics and 30 obese diabetics on Metformin were recruited for the study. Fasting blood samples were collected and PBMC were isolated from whole blood. Polarization markers (CD86, IL-6, TNFα, iNOS, CD36, CD11c, CD169, CD206, CD163, CD68, CD11b, CD16, and CD14) were measured by RT-qPCR. Gene expression fold changes were calculated using the 2(−ΔΔCT) method for RT-qPCR. Results: Obesity and T2DM are associated an increased CD68 marker in PBMC. mRNA expression of CD11b, CD11c, CD169, and CD163 were significantly reduced in PBMC from T2DM subjects whereas CD11c was significantly inhibited in PBMC from obese subjects. On the other hand, macrophage M1-like phenotype was observed in T2DM circulation as demonstrated by increased mRNA expression of CD16, IL-6, iNOS, TNFα, and CD36. There were no significant changes in CD14 and CD86 in the obese and T2DM when compared to the lean subjects. Metformin treatment in T2DM reverted CD11c, CD169, IL-6, iNOS, TNFα, and CD36 to levels comparable to lean subjects. CD206 mRNA expression was significantly upregulated in PBMC of T2DM while Metformin treatment inhibited CD206 expression levels. Conclusions: These data support the notion that PBMC in circulation in T2DM express different pattern of phenotypic markers than the patterns typically present in M1 and M2 like cells. These phenotypic markers could be representative of metabolically activated macrophages (MMe)-like cells. Metformin, on the other hand, reduces MMe-like cells in circulation.
format Online
Article
Text
id pubmed-6189318
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-61893182018-10-23 Differential Expression of Human Peripheral Mononuclear Cells Phenotype Markers in Type 2 Diabetic Patients and Type 2 Diabetic Patients on Metformin Al Dubayee, Mohammed S. Alayed, Hind Almansour, Rana Alqaoud, Nora Alnamlah, Rahaf Obeid, Dana Alshahrani, Awad Zahra, Mahmoud M. Nasr, Amre Al-Bawab, Ahmad Aljada, Ahmad Front Endocrinol (Lausanne) Endocrinology Background: Although peripheral blood mononuclear cells (PBMC) have been demonstrated to be in a pro-inflammatory state in obesity and type 2 Diabetes Mellitus (T2DM), characterization of circulating PBMC phenotypes in the obese and T2DM and the effect of Metformin on these phenotypes in humans is still ill-defined and remains to be determined. Methods: Thirty normal healthy adult volunteers of normal weight, 30 obese subjects, 20 obese newly diagnosed diabetics and 30 obese diabetics on Metformin were recruited for the study. Fasting blood samples were collected and PBMC were isolated from whole blood. Polarization markers (CD86, IL-6, TNFα, iNOS, CD36, CD11c, CD169, CD206, CD163, CD68, CD11b, CD16, and CD14) were measured by RT-qPCR. Gene expression fold changes were calculated using the 2(−ΔΔCT) method for RT-qPCR. Results: Obesity and T2DM are associated an increased CD68 marker in PBMC. mRNA expression of CD11b, CD11c, CD169, and CD163 were significantly reduced in PBMC from T2DM subjects whereas CD11c was significantly inhibited in PBMC from obese subjects. On the other hand, macrophage M1-like phenotype was observed in T2DM circulation as demonstrated by increased mRNA expression of CD16, IL-6, iNOS, TNFα, and CD36. There were no significant changes in CD14 and CD86 in the obese and T2DM when compared to the lean subjects. Metformin treatment in T2DM reverted CD11c, CD169, IL-6, iNOS, TNFα, and CD36 to levels comparable to lean subjects. CD206 mRNA expression was significantly upregulated in PBMC of T2DM while Metformin treatment inhibited CD206 expression levels. Conclusions: These data support the notion that PBMC in circulation in T2DM express different pattern of phenotypic markers than the patterns typically present in M1 and M2 like cells. These phenotypic markers could be representative of metabolically activated macrophages (MMe)-like cells. Metformin, on the other hand, reduces MMe-like cells in circulation. Frontiers Media S.A. 2018-10-09 /pmc/articles/PMC6189318/ /pubmed/30356719 http://dx.doi.org/10.3389/fendo.2018.00537 Text en Copyright © 2018 Al Dubayee, Alayed, Almansour, Alqaoud, Alnamlah, Obeid, Alshahrani, Zahra, Nasr, Al-Bawab and Aljada. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Al Dubayee, Mohammed S.
Alayed, Hind
Almansour, Rana
Alqaoud, Nora
Alnamlah, Rahaf
Obeid, Dana
Alshahrani, Awad
Zahra, Mahmoud M.
Nasr, Amre
Al-Bawab, Ahmad
Aljada, Ahmad
Differential Expression of Human Peripheral Mononuclear Cells Phenotype Markers in Type 2 Diabetic Patients and Type 2 Diabetic Patients on Metformin
title Differential Expression of Human Peripheral Mononuclear Cells Phenotype Markers in Type 2 Diabetic Patients and Type 2 Diabetic Patients on Metformin
title_full Differential Expression of Human Peripheral Mononuclear Cells Phenotype Markers in Type 2 Diabetic Patients and Type 2 Diabetic Patients on Metformin
title_fullStr Differential Expression of Human Peripheral Mononuclear Cells Phenotype Markers in Type 2 Diabetic Patients and Type 2 Diabetic Patients on Metformin
title_full_unstemmed Differential Expression of Human Peripheral Mononuclear Cells Phenotype Markers in Type 2 Diabetic Patients and Type 2 Diabetic Patients on Metformin
title_short Differential Expression of Human Peripheral Mononuclear Cells Phenotype Markers in Type 2 Diabetic Patients and Type 2 Diabetic Patients on Metformin
title_sort differential expression of human peripheral mononuclear cells phenotype markers in type 2 diabetic patients and type 2 diabetic patients on metformin
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189318/
https://www.ncbi.nlm.nih.gov/pubmed/30356719
http://dx.doi.org/10.3389/fendo.2018.00537
work_keys_str_mv AT aldubayeemohammeds differentialexpressionofhumanperipheralmononuclearcellsphenotypemarkersintype2diabeticpatientsandtype2diabeticpatientsonmetformin
AT alayedhind differentialexpressionofhumanperipheralmononuclearcellsphenotypemarkersintype2diabeticpatientsandtype2diabeticpatientsonmetformin
AT almansourrana differentialexpressionofhumanperipheralmononuclearcellsphenotypemarkersintype2diabeticpatientsandtype2diabeticpatientsonmetformin
AT alqaoudnora differentialexpressionofhumanperipheralmononuclearcellsphenotypemarkersintype2diabeticpatientsandtype2diabeticpatientsonmetformin
AT alnamlahrahaf differentialexpressionofhumanperipheralmononuclearcellsphenotypemarkersintype2diabeticpatientsandtype2diabeticpatientsonmetformin
AT obeiddana differentialexpressionofhumanperipheralmononuclearcellsphenotypemarkersintype2diabeticpatientsandtype2diabeticpatientsonmetformin
AT alshahraniawad differentialexpressionofhumanperipheralmononuclearcellsphenotypemarkersintype2diabeticpatientsandtype2diabeticpatientsonmetformin
AT zahramahmoudm differentialexpressionofhumanperipheralmononuclearcellsphenotypemarkersintype2diabeticpatientsandtype2diabeticpatientsonmetformin
AT nasramre differentialexpressionofhumanperipheralmononuclearcellsphenotypemarkersintype2diabeticpatientsandtype2diabeticpatientsonmetformin
AT albawabahmad differentialexpressionofhumanperipheralmononuclearcellsphenotypemarkersintype2diabeticpatientsandtype2diabeticpatientsonmetformin
AT aljadaahmad differentialexpressionofhumanperipheralmononuclearcellsphenotypemarkersintype2diabeticpatientsandtype2diabeticpatientsonmetformin